The Emirates Drug Establishment granted conditional approval for a new use of AstraZeneca’s Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy who face a high risk of disease progression. This decision positions the UAE as the first nation globally to authorise the indication for the complement inhibitor, which is administered intravenously. The Emirates Drug Establishment emphasised that the approval followed a rigorous scientific assessment balancing innovation with standards of safety, quality and efficacy. Primary IgA nephropathy, an immune-mediated condition, results from the deposition of immunoglobulin A in kidney tissue, triggering inflammation that can lead to a progressive loss of function.
A review of global incidence data published in Nephrology Dialysis Transplantation places the adult rate of IgA nephropathy at roughly 2.5 cases per 100,000 people annually. Studies of glomerular disease patterns across Arab countries, compiled in a systematic review, show the condition accounts for between 4 and 8 percent of primary glomerular disease cases. Elevated protein levels in urine serve as a critical marker of progression, and treatments that lower proteinuria can slow the decline toward kidney failure. Up to half of patients may reach end-stage kidney disease within 10 to 20 years without effective intervention. A recent meta-analysis of more than 15,000 patients found that even low-grade proteinuria between 0.5 and 1.0 grams per day raises the risk of adverse kidney outcomes by 73 percent compared with levels below 0.5 grams.
The conditional approval expands Ultomiris indications in the UAE, where the medicine has carried registration since 2022 for treating several rare diseases. The Emirates Drug Establishment noted that the move aligns with national priorities under the We the UAE 2031 vision to advance healthcare innovation and pharmaceutical leadership. Officials highlighted the need for early diagnosis together with regular monitoring of kidney function and urinary protein levels. Patients should adhere strictly to regimens prescribed by specialist physicians to manage the condition and minimise complications.
Dr Ruqaya Aqeel Al Bastaki, acting executive director of the medical products regulation sector at the Emirates Drug Establishment, described the regulatory framework as one that keeps pace with pharmaceutical advances while upholding the highest standards. The official added that the approval demonstrates the effectiveness of this balanced approach in accelerating access to new therapies. Her comments came in the announcement detailing the scientific basis for the decision.
Sameh El Fangary, Gulf Cluster president at AstraZeneca, characterised the conditional approval as an important step toward broadening treatment options for eligible patients in the UAE. The executive said his company looks forward to ongoing collaboration with local partners to improve access, treatment outcomes and overall quality of care. AstraZeneca developed ravulizumab, marketed as Ultomiris, as a long-acting C5 complement inhibitor that has established use across multiple rare conditions.
The development arrives as global health authorities, including the US Food and Drug Administration, have also moved toward approvals for complement inhibitors in IgA nephropathy based on proteinuria reduction data. Industry assessments indicate that such therapies address a significant unmet need in a disease that remains the most common form of primary glomerulonephritis worldwide. The Emirates Drug Establishment continues to evaluate emerging treatments to strengthen the country’s position in pharmaceutical regulation and patient care.
ع